96 research outputs found

    Π¦Π˜Π€Π ΠžΠ’ΠžΠ• Π”Π˜Π€Π€Π•Π Π•ΠΠ¦Π˜Π ΠžΠ’ΠΠΠ˜Π• Π‘Π˜Π“ΠΠΠ›ΠžΠ’ Π‘ Π˜Π‘ΠŸΠžΠ›Π¬Π—ΠžΠ’ΠΠΠ˜Π•Πœ Π˜ΠΠ’Π•Π“Π ΠΠ›Π¬ΠΠ«Π₯ Π£Π ΠΠ’ΠΠ•ΠΠ˜Π™ Π’ΠžΠ›Π¬Π’Π•Π Π Π, И Π•Π“Πž ΠŸΠ Π˜ΠœΠ•ΠΠ•ΠΠ˜Π• Π”Π›Π― ΠœΠžΠ”Π•Π›Π˜Π ΠžΠ’ΠΠΠ˜Π― Π‘Π˜Π‘Π’Π•Πœ Π£ΠŸΠ ΠΠ’Π›Π•ΠΠ˜Π― И ΠšΠžΠΠ’Π ΠžΠ›Π― Π’ Π‘Π˜Π›ΠžΠ’ΠžΠ™ Π­Π›Π•ΠšΠ’Π ΠžΠΠ˜ΠšΠ•

    Get PDF
    In article the new original way of digital differentiation of the signals, intended for use in real time is offered and investigated. The way is based on application of the integrated equations of Volterra I of a sort. Some results of pilot studies illustrating its working capacity and suitability for use in systems of automatic control of real time are given.Π’ Π΄Π°Π½Π½ΠΎΠΉ Ρ€Π°Π±ΠΎΡ‚Π΅ ΠΏΡ€Π΅Π΄Π»ΠΎΠΆΠ΅Π½ ΠΈ исслСдован Π½ΠΎΠ²Ρ‹ΠΉ ΠΎΡ€ΠΈΠ³ΠΈΠ½Π°Π»ΡŒΠ½Ρ‹ΠΉ способ Ρ†ΠΈΡ„Ρ€ΠΎΠ²ΠΎΠ³ΠΎ диффСрСнцирования сигналов, ΠΏΡ€Π΅Π΄Π½Π°Π·Π½Π°Ρ‡Π΅Π½Π½Ρ‹ΠΉ для использования Π² Ρ€Π΅Π°Π»ΡŒΠ½ΠΎΠΌ ΠΌΠ°ΡΡˆΡ‚Π°Π±Π΅ Π²Ρ€Π΅ΠΌΠ΅Π½ΠΈ. Бпособ основан Π½Π° ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ ΠΈΠ½Ρ‚Π΅Π³Ρ€Π°Π»ΡŒΠ½Ρ‹Ρ… ΡƒΡ€Π°Π²Π½Π΅Π½ΠΈΠΉ Π’ΠΎΠ»ΡŒΡ‚Π΅Ρ€Ρ€Π°Β IΒ Ρ€ΠΎΠ΄Π°. ΠŸΡ€ΠΈΠ²Π΅Π΄Π΅Π½Ρ‹ Π½Π΅ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ ΡΠΊΡΠΏΠ΅Ρ€ΠΈΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½Ρ‹Ρ… исслСдований, ΠΈΠ»Π»ΡŽΡΡ‚Ρ€ΠΈΡ€ΡƒΡŽΡ‰ΠΈΠ΅ Π΅Π³ΠΎ Ρ€Π°Π±ΠΎΡ‚ΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡ‚ΡŒ ΠΈ ΠΏΡ€ΠΈΠ³ΠΎΠ΄Π½ΠΎΡΡ‚ΡŒ для использования Π² систСмах автоматичСского управлСния Ρ€Π΅Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ Π²Ρ€Π΅ΠΌΠ΅Π½ΠΈ

    Peculiarities of the Regulatory Status of Radiopharmaceuticals Manufactured in Medical Organisations

    Get PDF
    Radiopharmaceuticals, the medicinal products containing radioactive isotopes, hold a special place among the other medicines. The aim of the study was to analyse regulatory peculiarities of the production and subsequent life cycle of radiopharmaceuticals, associated with the unique physicochemical properties, production process, distribution, and clinical use. The article reviews regulatory decisions adopted in Russia and a number of other countries that, in certain circumstances, allow medical organisations not licensed as manufacturers to compound radiopharmaceuticals for in-house use without marketing authorisation. Unstable isotopes in radiopharmaceuticals reduce the risk of microbial contamination, so the quality control requirements may be relaxed. The described regulatory framework, which came into effect 12 years ago, provided an opportunity for a many-fold increase in the number of radiopharmaceuticals for radionuclide diagnosis and treatment of severe socially significant diseases. In recent years, a number of countries have adopted regulations making it possible to Β supply the Β radiopharmaceuticals manufactured by medical organisations outside the usual marketing authorisation track to other medical organisations. If adopted in Russia, a similar regulation will further expand the access to effective methods of diagnosis and treatment for patients

    Potential of Theranostics in Visualisation of the Tumour Microenvironment and Elimination of Its Immunosuppressive Components

    Get PDF
    Theranostics is a promising branch of nuclear medicine that uses radiopharmaceuticals for diagnosis and treatment of cancer, and immunotheranostics is a special area in it. The aim of the study was to summarise the potential of theranostics for visualisation of the tumour microenvironment and elimination of its immunosuppressive components. The article presents up-to-date information on the composition and interaction of various cell subpopulations in the tumour microenvironment, as well as on the role of cancer stem cells in its formation. It describes defects of signalling pathways and potential targets for theranostics of cancer stem cells. Also, the article provides a description of the mechanism of interaction between the tumour and the immune system in the process of carcinogenesis. The review offers a detailed analysis of approaches to assessing the type of tumour microenvironment in order to individualise treatment and develop a rational design of clinical studies of theranostic couples. The authors present their own data on the distribution of subpopulations of lymphocytes and myeloid-derived suppressor cells in patients with metastatic tumours. The authors have considered the nuances of creating and using various molecules for targeted delivery in the development of diagnostic and therapeutic radiopharmaceuticals. The most promising diagnostic and therapeutic isotopes are described from the point of view of assessing the microenvironment and the possibility of influencing it. The article highlights modern and promising methods of pre-targeting to reduce the toxicity and increase the effectiveness of theranostics. Furthermore, having compared the advantages and disadvantages of theranostics with those of other systemic treatment options for metastatic tumours, the authors outline possible ways to overcome the shortcomings of theranostics

    Buoyancy-driven flow inside an asymmetrically heated cavity

    Get PDF
    Buoyancy-driven flows inside enclosures are in the center of problems related to heat transfer because they can provide a significant insight into the physical mechanisms of heat transfer. Typical examples of such flows include Rayleigh–BΓ©nard convection, differentially heated cavities and partially divided enclosures. In the present study, the buoyancy-driven flow inside an asymmetrically heated closed cavity is investigated and proposed as a benchmark case for future studies to assess the accuracy of simulations and to help in the validation of coarsened turbulence models. Additionally, from an application perspective such a configuration is highly relevant, e.g., in view of its similarity with passive solar systems such as ventilated building facades (Puangsombuta et al, J Fluid Mech 42(6):2218–2226, 2007, [1]) and Trombe walls (Zamora and Kaiser, Heat Mass Transf 45(11):1393–1407, 2009, [2]).</p

    ΠŸΠΎΠ³Ρ€Π΅ΡˆΠ½ΠΎΡΡ‚ΡŒ сканирования ΠΎΠ±Ρ‚ΡŽΡ€Π°Ρ‚ΠΎΡ€Π½Ρ‹Ρ… ΠΏΡ€ΠΈΠ±ΠΎΡ€ΠΎΠ²

    Get PDF
    ΠŸΡ€ΠΎΠ²Π΅Π΄Π΅Π½Ρ– дослідТСння Ρ–Π½ΡΡ‚Ρ€ΡƒΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½ΠΎΡ— ΠΏΠΎΡ…ΠΈΠ±ΠΊΠΈ ΠΎΠ±Ρ‚ΡŽΡ€Π°Ρ‚ΠΎΡ€Π½ΠΈΡ… ΠΏΡ€ΠΈΠ»Π°Π΄Ρ–Π².Π’ΠΈΠ·Π½Π°Ρ‡Π΅Π½Ρ– Π΄ΠΆΠ΅Ρ€Π΅Π»Π° ΠΏΠΎΡ…ΠΈΠ±ΠΊΠΈ, Π²ΠΏΠ»ΠΈΠ² Ρ„ΠΎΡ€ΠΌΠΈ сигналів. НавСдСні дСякі Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†Ρ–Ρ— Ρ‰ΠΎΠ΄ΠΎ змСншСння ΠΏΠΎΡ…ΠΈΠ±ΠΊΠΈ сканування.Studies have been conducted on the fault of obturator devises (fault of scanning), which has been preconditioned by configuration changes of measuring optical channel. The channel has been connected with obturator, which constantly is changing the position of the opening. The opening passing the optical informative parameter.The sources of the fault and the influence have been of the forms of signals detected. Certain recommendation on decrease of the scan fault has been provided.ΠŸΡ€ΠΎΠ²Π΅Π΄Π΅Π½Ρ‹ исслСдования ΠΈΠ½ΡΡ‚Ρ€ΡƒΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½ΠΎΠΉ ΠΏΠΎΠ³Ρ€Π΅ΡˆΠ½ΠΎΡΡ‚ΠΈ ΠΎΠ±Ρ‚ΡŽΡ€Π°Ρ‚ΠΎΡ€Π½Ρ‹Ρ… ΠΏΡ€ΠΈΠ±ΠΎΡ€ΠΎΠ² (ΠΏΠΎΠ³Ρ€Π΅ΡˆΠ½ΠΎΡΡ‚ΠΈ сканирования), которая обусловлСна ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠ½Ρ„ΠΈΠ³ΡƒΡ€Π°Ρ†ΠΈΠΈ ΠΈΠ·ΠΌΠ΅Ρ€ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ оптичСского ΠΊΠ°Π½Π°Π»Π°, связанным с Π½Π°Π»ΠΈΡ‡ΠΈΠ΅ΠΌ ΠΎΠ±Ρ‚ΡŽΡ€Π°Ρ‚ΠΎΡ€Π°, постоянно ΠΈ постСпСнно ΠΈΠ·ΠΌΠ΅Π½ΡΡŽΡ‰Π΅Π³ΠΎ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ ΠΎΠΊΠ½Π°, ΠΏΡ€ΠΎΠΏΡƒΡΠΊΠ°ΡŽΡ‰Π΅Π³ΠΎ оптичСский ΠΈΠ½Ρ„ΠΎΡ€ΠΌΠ°Ρ‚ΠΈΠ²Π½Ρ‹ΠΉ ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€. ΠžΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½Ρ‹ источники ΠΏΠΎΠ³Ρ€Π΅ΡˆΠ½ΠΎΡΡ‚ΠΈ, влияниС Ρ„ΠΎΡ€ΠΌΡ‹ сигналов. Π”Π°Π½Ρ‹ Π½Π΅ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†ΠΈΠΈ ΠΏΠΎ ΡƒΠΌΠ΅Π½ΡŒΡˆΠ΅Π½ΠΈΡŽ ΠΏΠΎΠ³Ρ€Π΅ΡˆΠ½ΠΎΡΡ‚ΠΈ сканирования

    ΠžΡΠΎΠ±Π΅Π½Π½ΠΎΡΡ‚ΠΈ рСгуляторного статуса радиофармацСвтичСских лСкарствСнных ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΎΠ², ΠΈΠ·Π³ΠΎΡ‚Π°Π²Π»ΠΈΠ²Π°Π΅ΠΌΡ‹Ρ… Π² мСдицинских организациях

    Get PDF
    Radiopharmaceuticals, the medicinal products containing radioactive isotopes, hold a special place among the other medicines. The aim of the study was to analyse regulatory peculiarities of the production and subsequent life cycle of radiopharmaceuticals, associated with the unique physicochemical properties, production process, distribution, and clinical use. The article reviews regulatory decisions adopted in Russia and a number of other countries that, in certain circumstances, allow medical organisations not licensed as manufacturers to compound radiopharmaceuticals for in-house use without marketing authorisation. Unstable isotopes in radiopharmaceuticals reduce the risk of microbial contamination, so the quality control requirements may be relaxed. The described regulatory framework, which came into effect 12 years ago, provided an opportunity for a many-fold increase in the number of radiopharmaceuticals for radionuclide diagnosis and treatment of severe socially significant diseases. In recent years, a number of countries have adopted regulations making it possible to Β supply the Β radiopharmaceuticals manufactured by medical organisations outside the usual marketing authorisation track to other medical organisations. If adopted in Russia, a similar regulation will further expand the access to effective methods of diagnosis and treatment for patients.ОсобоС мСсто срСди лСкарствСнных ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΎΠ² Π·Π°Π½ΠΈΠΌΠ°ΡŽΡ‚ ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚Ρ‹, содСрТащиС Ρ€Π°Π΄ΠΈΠΎΠΈΠ·ΠΎΡ‚ΠΎΠΏΡ‹ Β β€” радиофармацСвтичСскиС лСкарствСнныС ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚Ρ‹ (Π Π€Π›ΠŸ). ЦСль Ρ€Π°Π±ΠΎΡ‚Ρ‹ Β β€” Π°Π½Π°Π»ΠΈΠ· особСнностСй рСгулирования производства ΠΈ обращСния Π Π€Π›ΠŸ, связанных со спСцификой ΠΈΡ… Ρ„ΠΈΠ·ΠΈΠΊΠΎ-химичСских свойств, Ρ‚Π΅Ρ…Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ изготовлСния, дистрибуции ΠΈ мСдицинского примСнСния. Показано, Ρ‡Ρ‚ΠΎ Π½Π°Π»ΠΈΡ‡ΠΈΠ΅ Π½Π΅ΡΡ‚Π°Π±ΠΈΠ»ΡŒΠ½Ρ‹Ρ… ΠΈΠ·ΠΎΡ‚ΠΎΠΏΠΎΠ² Π² составС ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΎΠ² сниТаСт риски микробиологичСского загрязнСния, Π² Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Π΅ Ρ‡Π΅Π³ΠΎ трСбования ΠΊ ΠΊΠΎΠ½Ρ‚Ρ€ΠΎΠ»ΡŽ качСства, ΠΏΡ€Π΅Π΄ΡŠΡΠ²Π»ΡΠ΅ΠΌΡ‹Π΅ ΠΊ Ρ‚Π°ΠΊΠΈΠΌ ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚Π°ΠΌ, ΠΌΠΎΠ³ΡƒΡ‚ Π±Ρ‹Ρ‚ΡŒ сниТСны. ΠŸΡ€ΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½Ρ‹ Π½ΠΎΡ€ΠΌΠ°Ρ‚ΠΈΠ²Π½Ρ‹Π΅ Π°ΠΊΡ‚Ρ‹, принятыС Π² России ΠΈ рядС Π΄Ρ€ΡƒΠ³ΠΈΡ… государств, согласно ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΌ Π² ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½Π½Ρ‹Ρ… условиях Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎ ΠΈΠ·Π³ΠΎΡ‚ΠΎΠ²Π»Π΅Π½ΠΈΠ΅ Π Π€Π›ΠŸ Π±Π΅Π· государствСнной рСгистрации нСпосрСдствСнно Π² мСдицинских организациях, Π½Π΅ ΠΈΠΌΠ΅ΡŽΡ‰ΠΈΡ… Π»ΠΈΡ†Π΅Π½Π·ΠΈΠΈ Π½Π° производство лСкарствСнных ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΎΠ², для собствСнного мСдицинского примСнСния. ΠžΠΏΠΈΡΠ°Π½Π½Ρ‹ΠΉ Ρ€Π΅ΠΆΠΈΠΌ, Π΄Π΅ΠΉΡΡ‚Π²ΡƒΡŽΡ‰ΠΈΠΉ Π² Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠ΅ послСдних 12 Π»Π΅Ρ‚ Π² Российской Π€Π΅Π΄Π΅Ρ€Π°Ρ†ΠΈΠΈ, ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ» ΡƒΠ²Π΅Π»ΠΈΡ‡ΠΈΡ‚ΡŒ Π² нСсколько Ρ€Π°Π· количСство Π Π€Π›ΠŸ, ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΡƒΠ΅ΠΌΡ‹Ρ… для Ρ€Π°Π΄ΠΈΠΎΠ½ΡƒΠΊΠ»ΠΈΠ΄Π½ΠΎΠΉ диагностики ΠΈ Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ тяТСлых ΡΠΎΡ†ΠΈΠ°Π»ΡŒΠ½ΠΎ Π·Π½Π°Ρ‡ΠΈΠΌΡ‹Ρ… Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ. Π’ послСдниС Π³ΠΎΠ΄Ρ‹ Π² рядС государств ΠΏΡ€ΠΈΠ½ΠΈΠΌΠ°ΡŽΡ‚ΡΡ Π½ΠΎΡ€ΠΌΠ°Ρ‚ΠΈΠ²Π½Ρ‹Π΅ Π°ΠΊΡ‚Ρ‹, Π² соотвСтствии с ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΌΠΈ прСдоставляСтся Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡ‚ΡŒ ΠΏΠΎΡΡ‚Π°Π²Π»ΡΡ‚ΡŒ Π Π€Π›ΠŸ, ΠΈΠ·Π³ΠΎΡ‚Π°Π²Π»ΠΈΠ²Π°Π΅ΠΌΡ‹Π΅ Π² мСдицинских организациях Π±Π΅Π· государствСнной рСгистрации, Π² Π΄Ρ€ΡƒΠ³ΠΈΠ΅ мСдицинскиС ΠΎΡ€Π³Π°Π½ΠΈΠ·Π°Ρ†ΠΈΠΈ. Π Π°Π·Ρ€Π°Π±ΠΎΡ‚ΠΊΠ° ΠΈ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ Π² дСйствиС Π°Π½Π°Π»ΠΎΠ³ΠΈΡ‡Π½Ρ‹Ρ… рСгуляторных Ρ€Π΅ΡˆΠ΅Π½ΠΈΠΉ Π½Π° Ρ‚Π΅Ρ€Ρ€ΠΈΡ‚ΠΎΡ€ΠΈΠΈ России ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ‚ Π² Π΅Ρ‰Π΅ большСй ΠΌΠ΅Ρ€Π΅ Ρ€Π°ΡΡˆΠΈΡ€ΠΈΡ‚ΡŒ доступ насСлСния ΠΊ эффСктивным ΠΌΠ΅Ρ‚ΠΎΠ΄Π°ΠΌ диагностики ΠΈ лСчСния

    ВозмоТности тСраностики Π² Π²ΠΈΠ·ΡƒΠ°Π»ΠΈΠ·Π°Ρ†ΠΈΠΈ микроокруТСния ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ ΠΈ элиминации Π΅Π³ΠΎ иммуносупрСссивных ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚ΠΎΠ²

    Get PDF
    Theranostics is a promising branch of nuclear medicine that uses radiopharmaceuticals for diagnosis and treatment of cancer, and immunotheranostics is a special area in it. The aim of the study was to summarise the potential of theranostics for visualisation of the tumour microenvironment and elimination of its immunosuppressive components. The article presents up-to-date information on the composition and interaction of various cell subpopulations in the tumour microenvironment, as well as on the role of cancer stem cells in its formation. It describes defects of signalling pathways and potential targets for theranostics of cancer stem cells. Also, the article provides a description of the mechanism of interaction between the tumour and the immune system in the process of carcinogenesis. The review offers a detailed analysis of approaches to assessing the type of tumour microenvironment in order to individualise treatment and develop a rational design of clinical studies of theranostic couples. The authors present their own data on the distribution of subpopulations of lymphocytes and myeloid-derived suppressor cells in patients with metastatic tumours. The authors have considered the nuances of creating and using various molecules for targeted delivery in the development of diagnostic and therapeutic radiopharmaceuticals. The most promising diagnostic and therapeutic isotopes are described from the point of view of assessing the microenvironment and the possibility of influencing it. The article highlights modern and promising methods of pre-targeting to reduce the toxicity and increase the effectiveness of theranostics. Furthermore, having compared the advantages and disadvantages of theranostics with those of other systemic treatment options for metastatic tumours, the authors outline possible ways to overcome the shortcomings of theranostics.Одним ΠΈΠ· пСрспСктивных Π½Π°ΠΏΡ€Π°Π²Π»Π΅Π½ΠΈΠΉ ядСрной ΠΌΠ΅Π΄ΠΈΡ†ΠΈΠ½Ρ‹ являСтся тСраностика β€” использованиС Ρ€Π°Π΄ΠΈΠΎΡ„Π°Ρ€ΠΌΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΎΠ² для диагностики ΠΈ лСчСния онкологичСских Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, особоС Π½Π°ΠΏΡ€Π°Π²Π»Π΅Π½ΠΈΠ΅ тСраностики β€” иммунотСраностика. ЦСль Ρ€Π°Π±ΠΎΡ‚Ρ‹ β€” ΠΎΠ±ΠΎΠ±Ρ‰ΠΈΡ‚ΡŒ возмоТности тСраностики Π² Π²ΠΈΠ·ΡƒΠ°Π»ΠΈΠ·Π°Ρ†ΠΈΠΈ микроокруТСния ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ ΠΈ элиминации Π΅Π³ΠΎ иммуносупрСссивных ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚ΠΎΠ². Π’ ΡΡ‚Π°Ρ‚ΡŒΠ΅ прСдставлСны Π΄Π°Π½Π½Ρ‹Π΅ ΠΎ составС ΠΈ взаимодСйствии Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… субпопуляций ΠΊΠ»Π΅Ρ‚ΠΎΠΊ Π² ΠΌΠΈΠΊΡ€ΠΎΠΎΠΊΡ€ΡƒΠΆΠ΅Π½ΠΈΠΈ ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ, Π° Ρ‚Π°ΠΊΠΆΠ΅ ΠΎ Ρ€ΠΎΠ»ΠΈ стволовых ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅Π²Ρ‹Ρ… ΠΊΠ»Π΅Ρ‚ΠΎΠΊ Π² Π΅Π³ΠΎ Ρ„ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠΈ. ΠžΠΏΠΈΡΠ°Π½Ρ‹ Π΄Π΅Ρ„Π΅ΠΊΡ‚Ρ‹ ΡΠΈΠ³Π½Π°Π»ΡŒΠ½Ρ‹Ρ… ΠΏΡƒΡ‚Π΅ΠΉ ΠΈ ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΠ°Π»ΡŒΠ½Ρ‹Π΅ мишСни для тСраностики стволовых ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅Π²Ρ‹Ρ… ΠΊΠ»Π΅Ρ‚ΠΎΠΊ, Π° Ρ‚Π°ΠΊΠΆΠ΅ ΠΌΠ΅Ρ…Π°Π½ΠΈΠ·ΠΌ взаимодСйствия ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ ΠΈ ΠΈΠΌΠΌΡƒΠ½Π½ΠΎΠΉ систСмы Π² процСссС ΠΊΠ°Π½Ρ†Π΅Ρ€ΠΎΠ³Π΅Π½Π΅Π·Π°. ΠŸΠΎΠ΄Ρ€ΠΎΠ±Π½ΠΎ Ρ€Π°Π·ΠΎΠ±Ρ€Π°Π½Ρ‹ ΠΏΠΎΠ΄Ρ…ΠΎΠ΄Ρ‹ ΠΊ ΠΎΡ†Π΅Π½ΠΊΠ΅ Ρ‚ΠΈΠΏΠ° микроокруТСния с Ρ†Π΅Π»ΡŒΡŽ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡƒΠ°Π»ΠΈΠ·Π°Ρ†ΠΈΠΈ лСчСния ΠΈ Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ Ρ€Π°Ρ†ΠΈΠΎΠ½Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ·Π°ΠΉΠ½Π° клиничСских исслСдований тСраностичСских ΠΏΠ°Ρ€. ΠŸΡ€ΠΈΠ²Π΅Π΄Π΅Π½Ρ‹ собствСнныС Π΄Π°Π½Π½Ρ‹Π΅ ΠΎ Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€Π΅ распрСдСлСния субпопуляций Π»ΠΈΠΌΡ„ΠΎΡ†ΠΈΡ‚ΠΎΠ² ΠΈ супрСссорных ΠΊΠ»Π΅Ρ‚ΠΎΠΊ ΠΌΠΈΠ΅Π»ΠΎΠΈΠ΄Π½ΠΎΠ³ΠΎ происхоТдСния Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с мСтастатичСскими Ρ„ΠΎΡ€ΠΌΠ°ΠΌΠΈ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ. РассмотрСны Π½ΡŽΠ°Π½ΡΡ‹ создания ΠΈ использования Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… ΠΌΠΎΠ»Π΅ΠΊΡƒΠ» адрСсной доставки ΠΏΡ€ΠΈ Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚ΠΊΠ΅ диагностичСских ΠΈ тСрапСвтичСских Ρ€Π°Π΄ΠΈΠΎΡ„Π°Ρ€ΠΌΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΎΠ². ΠžΠΏΠΈΡΠ°Π½Ρ‹ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ пСрспСктивныС диагностичСскиС ΠΈ тСрапСвтичСскиС ΠΈΠ·ΠΎΡ‚ΠΎΠΏΡ‹ с Ρ‚ΠΎΡ‡ΠΊΠΈ зрСния возмоТности ΠΎΡ†Π΅Π½ΠΊΠΈ микроокруТСния ΠΈ воздСйствия Π½Π° Π½Π΅Π³ΠΎ. Π’ ΡΡ‚Π°Ρ‚ΡŒΠ΅ освСщСны соврСмСнныС ΠΈ пСрспСктивныС ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹ ΠΏΡ€Π΅Π΄Π²Π°Ρ€ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ Ρ‚Π°Ρ€Π³Π΅Ρ‚ΠΈΠ½Π³Π° для сниТСния токсичности ΠΈ ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½ΠΈΡ эффСктивности тСраностики. РассмотрСны Ρ‚Π°ΠΊΠΆΠ΅ достоинства ΠΈ нСдостатки тСраностики ΠΏΠΎ ΡΡ€Π°Π²Π½Π΅Π½ΠΈΡŽ с Π΄Ρ€ΡƒΠ³ΠΈΠΌΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Π°ΠΌΠΈ систСмного лСчСния мСтастатичСских Ρ„ΠΎΡ€ΠΌ ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ. ΠžΠ±ΠΎΠ·Π½Π°Ρ‡Π΅Π½Ρ‹ ΠΏΡƒΡ‚ΠΈ прСодолСния нСдостатков тСраностики

    Унифицированная модСль расчСтов ΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ тСхничСских срСдств ΠΏΡ€ΠΈ Ρ€Π΅Π°Π»ΠΈΠ·Π°Ρ†ΠΈΠΈ транспортных ΠΈ транспортно­тСхнологичСских ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΉ

    Get PDF
    Productivity is one of the important performance indicators of transport and transport-technological vehicles. The authors confirmed the necessity to unify this indicator calculations for an extensive range of agricultural goods and extensive works on their movement. (Research purpose) To develop universal interconnected stages of detecting the operational productivity of transport and transport-technological vehicles when performing mechanized work in crop production. (Materials and methods) The values of operational performance were determined based on the analysis of norm-forming factors and statistical processing. A systematic approach was used to identifying individual elements of the cargo transportation cycle. The authors studied each of the methodological approaches and the mathematical tools used to calculate the performance indicators of various technical devices. (Results and discussion) After a step-by-step modeling of transport and transport-technological processes, a unified formula of the target function (optimality criterion) was obtained. Having implemented a more convenient calculation algorithm and having transformed the mathematical apparatus, the authors obtained the vehicle production rates for the transportation of mineral fertilizers to the place of their application. (Conclusions) The authors implemented a detailed mathematical description of the transport and transport-technological process stages. They identified the functional relationships between operational parameters and production and agrolandscape conditions.Β  A universal algorithm was developed making it possible to determine the values of the operational performance for transport and transport-technological vehicles. The authors determined the values of the coefficient enabling the unification and comparison of the algorithm for identifying the production rates for transport and transport-technological work. It was found out that with an increase in the length of transportation from 3 to 54 kilometers, this coefficient increases 3.8 times. This variation was explained by an increase in the purely transport phase of the process.ΠŸΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ – ΠΎΠ΄ΠΈΠ½ ΠΈΠ· Π²Π°ΠΆΠ½Ρ‹Ρ… эксплуатационных ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»Π΅ΠΉ транспортных ΠΈ транспортно-тСхнологичСских срСдств. ΠŸΠΎΠ΄Ρ‚Π²Π΅Ρ€Π΄ΠΈΠ»ΠΈ Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΠΎΡΡ‚ΡŒ ΡƒΠ½ΠΈΡ„ΠΈΡ†ΠΈΡ€ΠΎΠ²Π°Ρ‚ΡŒ расчСты этого показатСля Π½Π° Ρ„ΠΎΠ½Π΅ ΠΎΠ±ΡˆΠΈΡ€Π½ΠΎΠΉ Π½ΠΎΠΌΠ΅Π½ΠΊΠ»Π°Ρ‚ΡƒΡ€Ρ‹ ΡΠ΅Π»ΡŒΡΠΊΠΎΡ…ΠΎΠ·ΡΠΉΡΡ‚Π²Π΅Π½Π½Ρ‹Ρ… Π³Ρ€ΡƒΠ·ΠΎΠ² ΠΈ большого количСства Ρ€Π°Π±ΠΎΡ‚ ΠΏΠΎ ΠΈΡ… ΠΏΠ΅Ρ€Π΅ΠΌΠ΅Ρ‰Π΅Π½ΠΈΡŽ. (ЦСль исслСдования) Π Π°Π·Ρ€Π°Π±ΠΎΡ‚Π°Ρ‚ΡŒ ΡƒΠ½ΠΈΠ²Π΅Ρ€ΡΠ°Π»ΡŒΠ½Ρ‹Π΅ взаимосвязанныС этапы опрСдСлСния эксплуатационной ΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ транспортных ΠΈ транспортно-тСхнологичСских срСдств ΠΏΡ€ΠΈ Ρ€Π΅Π°Π»ΠΈΠ·Π°Ρ†ΠΈΠΈ ΠΌΠ΅Ρ…Π°Π½ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Ρ… Ρ€Π°Π±ΠΎΡ‚ Π² растСниСводствС. (ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹) ΠžΠΏΡ€Π΅Π΄Π΅Π»ΠΈΠ»ΠΈ значСния эксплуатационной ΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ посрСдством Π°Π½Π°Π»ΠΈΠ·Π° Π½ΠΎΡ€ΠΌΠΎΠΎΠ±Ρ€Π°Π·ΡƒΡŽΡ‰ΠΈΡ… Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΎΠ² ΠΈ статистичСской ΠΎΠ±Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ. Использовали систСмный ΠΏΠΎΠ΄Ρ…ΠΎΠ΄ ΠΊ ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½ΠΈΡŽ ΠΎΡ‚Π΄Π΅Π»ΡŒΠ½Ρ‹Ρ… элСмСнтов Ρ†ΠΈΠΊΠ»Π° транспортировки Π³Ρ€ΡƒΠ·ΠΎΠ². Π˜Π·ΡƒΡ‡ΠΈΠ»ΠΈ ΠΊΠ°ΠΆΠ΄Ρ‹ΠΉ ΠΈΠ· мСтодичСских ΠΏΠΎΠ΄Ρ…ΠΎΠ΄ΠΎΠ² ΠΈ примСняСмыС матСматичСскиС Π°ΠΏΠΏΠ°Ρ€Π°Ρ‚Ρ‹ для опрСдСлСния ΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ тСхничСских срСдств Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… Ρ‚ΠΈΠΏΠΎΠ². (Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ ΠΈ обсуТдСниС) ПослС поэтапного модСлирования Ρ€Π΅Π°Π»ΠΈΠ·Π°Ρ†ΠΈΠΈ транспортных ΠΈ транспортно-тСхнологичСских процСссов ΠΏΠΎΠ»ΡƒΡ‡ΠΈΠ»ΠΈ ΡƒΠ½ΠΈΡ„ΠΈΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½ΡƒΡŽ Ρ„ΠΎΡ€ΠΌΡƒΠ»Ρƒ Ρ†Π΅Π»Π΅Π²ΠΎΠΉ Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΈ (критСрия ΠΎΠΏΡ‚ΠΈΠΌΠ°Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ). Π’ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Π΅ Ρ€Π΅Π°Π»ΠΈΠ·Π°Ρ†ΠΈΠΈ Π±ΠΎΠ»Π΅Π΅ ΡƒΠ΄ΠΎΠ±Π½ΠΎΠ³ΠΎ Π°Π»Π³ΠΎΡ€ΠΈΡ‚ΠΌΠ° расчСта ΠΈ прСобразования матСматичСского Π°ΠΏΠΏΠ°Ρ€Π°Ρ‚Π° вычислили значСния Π½ΠΎΡ€ΠΌ Π²Ρ‹Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ для транспортных срСдств ΠΏΡ€ΠΈ транспортировкС ΠΌΠΈΠ½Π΅Ρ€Π°Π»ΡŒΠ½Ρ‹Ρ… ΡƒΠ΄ΠΎΠ±Ρ€Π΅Π½ΠΈΠΉ ΠΊ мСсту ΠΈΡ… внСсСния. (Π’Ρ‹Π²ΠΎΠ΄Ρ‹) ΠŸΡ€ΠΎΠ²Π΅Π»ΠΈ Π΄Π΅Ρ‚Π°Π»ΡŒΠ½ΠΎΠ΅ матСматичСскоС описаниС этапов Ρ€Π΅Π°Π»ΠΈΠ·Π°Ρ†ΠΈΠΈ транспортного ΠΈ транспортно-тСхнологичСского процСсса. ΠžΠΏΡ€Π΅Π΄Π΅Π»ΠΈΠ»ΠΈ Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΎΠ½Π°Π»ΡŒΠ½Ρ‹Π΅ зависимости ΠΌΠ΅ΠΆΠ΄Ρƒ эксплуатационными ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€Π°ΠΌΠΈ ΠΈ производствСнными ΠΈ Π°Π³Ρ€ΠΎΠ»Π°Π½Π΄ΡˆΠ°Ρ„Ρ‚Π½Ρ‹ΠΌΠΈ условиями. Π Π°Π·Ρ€Π°Π±ΠΎΡ‚Π°Π»ΠΈ ΡƒΠ½ΠΈΠ²Π΅Ρ€ΡΠ°Π»ΡŒΠ½Ρ‹ΠΉ Π°Π»Π³ΠΎΡ€ΠΈΡ‚ΠΌ, для расчСта значСния эксплуатационной ΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ транспортных ΠΈ транспортно-тСхнологичСских срСдств. ΠžΠΏΡ€Π΅Π΄Π΅Π»ΠΈΠ»ΠΈ значСния коэффициСнта, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡŽΡ‰Π΅Π³ΠΎ ΡƒΠ½ΠΈΡ„ΠΈΡ†ΠΈΡ€ΠΎΠ²Π°Ρ‚ΡŒ ΠΈ ΡΠΎΠΏΠΎΡΡ‚Π°Π²ΠΈΡ‚ΡŒ Π°Π»Π³ΠΎΡ€ΠΈΡ‚ΠΌ вычислСния Π½ΠΎΡ€ΠΌ Π²Ρ‹Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ Π½Π° транспортныС ΠΈ транспортно-тСхнологичСскиС Ρ€Π°Π±ΠΎΡ‚Ρ‹. Выявили, Ρ‡Ρ‚ΠΎ с ΡƒΠ²Π΅Π»ΠΈΡ‡Π΅Π½ΠΈΠ΅ΠΌ Π΄Π»ΠΈΠ½Ρ‹ транспортировки ΠΎΡ‚ 3 Π΄ΠΎ 54 ΠΊΠΈΠ»ΠΎΠΌΠ΅Ρ‚Ρ€ΠΎΠ² этот коэффициСнт ΠΏΠΎΠ²Ρ‹ΡˆΠ°Π΅Ρ‚ΡΡ 3,8 Ρ€Π°Π·Π°. Π”Π°Π½Π½ΠΎΠ΅ Π²Π°Ρ€ΡŒΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠ΅ объяснили ростом чисто транспортной Ρ„Π°Π·Ρ‹ выполнСния процСсса.
    • …
    corecore